Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 23.
Article
Bevers, Lisanne AH;
Waalewijn, Hylke;
Szubert, Alexander J;
Chabala, Chishala;
Bwakura-Dangarembizi, Mutsa;
Makumbi, Shafic;
Nangiya, Joan;
... Colbers, Angela; + view all
(2023)
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial.
Clinical Infectious Diseases
10.1093/cid/ciad346.
(In press).
|
|
Bourke, C;
Gough, E;
Pimundu, G;
Shonhai, A;
Berejena, C;
Terry, L;
Baumard, L;
... Prendergast, AJ; + view all
(2019)
Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation.
Science Translational Medicine
, 11
(486)
, Article eaav0537. 10.1126/scitranslmed.aav0537.
|
|
Bwakura-Dangarembizi, M;
Musiime, V;
Szubert, AJ;
Prendergast, AJ;
Gomo, ZA;
Thomason, MJ;
Musarurwa, C;
... Nathoo, K; + view all
(2015)
Prevalence of Lipodystrophy and Metabolic Abnormalities in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy.
Pediatr Infect Dis J
, 34
(2)
e23 - e31.
10.1097/INF.0000000000000491.
|
 |
|
Hakim, J;
Musiime, V;
Szubert, AJ;
Mallewa, J;
Siika, A;
Agutu, C;
Walker, S;
... Gibb, DM; + view all
(2017)
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
New England Journal of Medicine
, 377
(3)
pp. 233-245.
10.1056/NEJMoa1615822.
|
|
Kamphuis, AEM;
Kiezebrink, T;
Waalewijn, H;
Bamford, A;
Szubert, AJ;
Chabala, C;
Bwakura-Dangarembizi, M;
... Burger, DM; + view all
(2025)
Pharmacokinetics of lopinavir/ritonavir in second-line treatment of children living with HIV in the CHAPAS-4 trial.
AIDS
10.1097/QAD.0000000000004328.
(In press).
|
 |
|
Kekitiinwa, A;
Szubert, AJ;
Spyer, M;
Katuramu, R;
Musiime, V;
Mhute, T;
Bakeera-Kitaka, S;
... ARROW Trial Team, .; + view all
(2017)
Virologic Response to First-Line Efavirenz- or Nevirapine-Based Anti-Retroviral Therapy in HIV-Infected African Children.
Pediatric Infectious Disease Journal
, 36
(6)
pp. 588-594.
10.1097/INF.0000000000001505.
|
|
|
Kityo, C;
Szubert, A;
Siika, A;
Heyderman, R;
Bwakura-Dangarembizi, M;
Lugemwa, A;
Mwaringa, S;
... Pett, S; + view all
(2018)
Raltegravir-intensified initial antiretroviral therapy in advanced HIV in Africa: a randomized controlled trial.
PLoS Medicine
, 15
(12)
, Article e1002706. 10.1371/journal..
|
|
|
Mallewa, J;
Szubert, AJ;
Mugyenyi, P;
Chidziva, E;
Thomason, MJ;
Chepkorir, P;
Abongomera, G;
... REALITY trial team, .; + view all
(2018)
Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.
The Lancet HIV
, 5
(5)
e231-e240.
10.1016/S2352-3018(18)30038-9.
|
|
Musoke, P;
Szubert, AJ;
Musiime, V;
Nathoo, K;
Nahirya-Ntege, P;
Mutasa, K;
Williams, DE;
... Gibb, DM; + view all
(2015)
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
AIDS
, 29
(13)
pp. 1623-1632.
10.1097/QAD.0000000000000749.
|
|
Pollock, KM;
Cheeseman, HM;
Szubert, AJ;
Libri, V;
Boffito, M;
Owen, D;
Bern, H;
... COVAC1 study Group; + view all
(2022)
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.
EClinicalMedicine
, 44
, Article 101262. 10.1016/j.eclinm.2021.101262.
|
|
|
Post, FA;
Szubert, AJ;
Prendergast, AJ;
Johnston, V;
Lyall, H;
Fitzgerald, F;
Musiime, V;
... Pett, SL; + view all
(2018)
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.
Clinical Infectious Diseases
, 66
(S2)
S132-S139.
10.1093/cid/cix1141.
|
|
|
Prendergast, A;
Szubert, A;
Berejena, C;
Pimundu, G;
Pala, P;
Shonhai, A;
Musiime, V;
... Klein, N; + view all
(2016)
Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy.
Journal of Infectious Diseases
, 214
(2)
pp. 226-236.
10.1093/infdis/jiw148.
|
|
Prendergast, AJ;
Berejena, C;
Pimundu, G;
Shonhai, A;
Bwakura-Dangarembizi, M;
Musiime, V;
Szubert, AJ;
... Walker, AS; + view all
(2019)
Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe.
AIDS
, 33
(9)
pp. 1485-1490.
10.1097/QAD.0000000000002231.
|
|
Prendergast, AJ;
Szubert, AJ;
Pimundu, G;
Berejena, C;
Pala, P;
Shonhai, A;
Hunter, P;
... Klein, N; + view all
(2021)
The impact of viraemia on inflammatory biomarkers and CD4 cell subpopulations in HIV-infected children in sub-Saharan Africa.
AIDS
, 35
(10)
pp. 1537-1548.
10.1097/QAD.0000000000002916.
(In press).
|
|
|
Prendergast, AJ;
Szubert, AJ;
Spyer, MJ;
Musiime, V;
Musoke, P;
Bwakura-Dangarembizi, M;
Nahirya-Ntege, P;
... Walker, AS; + view all
(2017)
Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
PLOS Medicine
, 14
(11)
, Article e1002432. 10.1371/journal.pmed.1002432.
|
|
|
Siika, A;
McCabe, L;
Bwakura-Dangarembizi, M;
Kityo, C;
Mallewa, J;
Berkley, J;
Maitland, K;
... Gibb, DM; + view all
(2018)
Late presentation with HIV in Africa: phenotypes, risk and risk stratification in the REALITY trial.
Clinical Infectious Diseases
, 66
(S2)
S140-S146.
10.1093/cid/cix1142.
|
|
Szubert, Alex J;
Pollock, Katrina M;
Cheeseman, Hannah M;
Alagaratnam, Jasmini;
Bern, Henry;
Bird, Olivia;
Boffito, Marta;
... COVAC 1 Study Team; + view all
(2023)
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2.
EClinicalMedicine
, 56
, Article 101823. 10.1016/j.eclinm.2022.101823.
|
|
Szubert, AJ;
Bailey, SL;
Cooke, GS;
Peto, TEA;
Llewelyn, MJ;
Edgeworth, JD;
Walker, A;
(2019)
Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: observational analyses within the ARREST trial.
Journal of Infection
, 79
(4)
pp. 332-340.
10.1016/j.jinf.2019.08.001.
|
|
Szubert, AJ;
Musiime, V;
Bwakura-Dangarembizi, M;
Nahirya-Ntege, P;
Kekitiinwa, A;
Gibb, DM;
Nathoo, K;
... ARROW Trial Team, ; + view all
(2015)
Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
AIDS
, 29
(5)
609 - 618.
10.1097/QAD.0000000000000590.
|
|
|
Thwaites, GE;
Scarborough, M;
Szubert, AJ;
Nsutebu, N;
Tilley, R;
Greig, J;
Wyllie, SA;
... Walker, AS; + view all
(2017)
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): a multi-centre, randomised, blinded, placebo controlled trial.
The Lancet
10.1016/S0140-6736(17)32456-X.
(In press).
|
|
|
Thwaites, GE;
Scarborough, M;
Szubert, AJ;
Saramango Concalves, P;
Soares, M;
Bostock, J;
Nsutebu, E;
... Walker, AS; + view all
(2018)
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.
Health Technology Assessment
, 22
(59)
10.3310/hta22590.
|
|
|
Thwaites, GE;
Szubert, A;
Walker, AS;
(2018)
Rifampicin in treating S aureus bacteraemia - Authors' reply.
The Lancet
, 392
(10147)
pp. 555-556.
10.1016/S0140-6736(18)31545-9.
|
|
Walker, S;
Cox, E;
Revill, P;
Musiime, V;
Bwakura-Dangarembizi, M;
Mallewa, J;
Cheruiyot, P;
... Soares, M; + view all
(2020)
The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.
Journal of the International AIDS Society
, 23
(3)
, Article e25469. 10.1002/jia2.25469.
|
|
